2 minute read | July.02.2026
Français: Orrick conseille Abivax dans le cadre de sa levée record de 920 millions de dollars sur le Nasdaq
Abivax SA, a clinical-stage biotechnology company, has completed a public offering of approximately $920 million (€807 million) through the issuance of American Depositary Shares on the Nasdaq Global Market. The offering represents a significant milestone for the French biotech sector and values the company at more than €10 billion.
Orrick advised Abivax on the structuring and implementation of this transaction.
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.
This offering will fund expenses relating to the potential commercialization of obefazimod in the U.S., clinical research and development expenses primarily related to ulcerative colitis and Crohn's disease, and general corporate purposes.
The transaction marks a transformative milestone for Abivax, positioning it among the most highly valued European biotechs, and providing the resources to advance its lead candidate through late-stage development and potential commercial launch.
The Orrick team is led by Alain Decombe and Vianney Toulouse, and includes Mathilde Duchamp and Léa Boutin.
Advising on tax aspects is led by Cécile Mariotti, and includes Maïten Le Brishoual.